CasNx is developing the next-wave of CRISPR-based technologies

Future CRISPR editors

Over 10,000 human diseases are estimated to be monogenic (caused by a single gene)

Small molecules and antibody drugs can only target 0.05% of the human genome. In contrast, CRISPR-based editors can target any gene, transcript, or protein

AI-powered CRISPR

CasNx is harnessing the power of Artificial Intelligence to make CRISPR technologies safer, more efficient, and cost-effective

Smart Diagnostics

Today’s molecular tests are slow, tedious, expensive, and error-prone.

CasNx is at the forefront of developing innovative solutions for point-of-care testing

Reach out via email at contact@casnx.com to learn more about work